Loo C

Black Dog Institute and University of New South Wales, Sydney, Australia.

9 papers · ORCID

ArticleKetamine

A Global Delphi-Based Expert Consensus on Relapse Prevention Strategies Following Successful Electroconvulsive Therapy for Major Depressive Disorder.

Rovers JJE, van Eijndhoven PFP, Abbot C +19

Europe PMC2026
ArticleKetamine

Time matters for metas: a systematic review and meta-analysis of ect vs ketamine for depression incorporating time.

Nikolin S, Massaneda-Tuneu C, Brettell L +1

Europe PMC2026
ArticleKetamine

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial: commentary, author response.

Loo C, Alonzo A, Barton D +9

Europe PMC2025
ArticleKetamine

Safety outcomes of ketamine for treatment-resistant depression in clinical settings and development of the ketamine side effect tool-revised (KSET-R).

Bayes A, Cao TV, Barreiros AR +10

Europe PMC2025
ArticleKetamine

Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial.

Glue P, Loo C, Fam J +3

Europe PMC2024
ArticleKetamine

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial.

Loo C, Glozier N, Barton D +35

Europe PMC2023
ArticleKetamine

Ensuring the affordable becomes accessible-lessons from ketamine, a new treatment for severe depression.

Rodgers A, Bahceci D, Davey CG +4

Europe PMC2024
ArticleKetamine

Ketamine for the treatment of major depression: a systematic review and meta-analysis.

Nikolin S, Rodgers A, Schwaab A +4

Europe PMC2023
ArticlePsilocybin

Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm.

Perkins D, Sarris J, Rossell S +17

Europe PMC2021